Al-Fakhrany Omnia Momtaz, Elekhnawy Engy
Pharmaceutical Microbiology Department, Faculty of Pharmacy, Tanta University, Tanta, 31527, Egypt.
Mol Biol Rep. 2024 Apr 15;51(1):505. doi: 10.1007/s11033-024-09398-5.
Recent and continuing advances in gut microbiome research have pointed out the role of the gut microbiota as an unexplored source of potentially beneficial probiotic microbes. Along the lines of these advances, both public awareness and acceptance of probiotics are increasing. That's why; academic and industrial research is dedicated to identifying and investigating new microbial strains for the development of next-generation probiotics (NGPs). At this time, there is a growing interest in NGPs as biotherapeutics that alter the gut microbiome and affect various diseases development. In this work, we have focused on some emergent and promising NGPs, specifically Eubacterium hallii, Faecalibacterium prausnitzii, Roseburia spp., Akkermansia muciniphila, and Bacteroides fragilis, as their presence in the gut can have an impact on the development of various diseases. Emerging studies point out the beneficial roles of these NGPs and open up novel promising therapeutic options. Interestingly, these NGPs were found to enhance gastrointestinal immunity, enhance immunotherapy efficacy in cancer patients, retain the intestinal barrier integrity, generate valuable metabolites, especially short-chain fatty acids, and decrease complications of chemotherapy and radiotherapy. Although many of these NGPs are considered promising for the prevention and treatment of several chronic diseases, research on humans is still lacking. Therefore, approval of these microbes from regulatory agencies is rare. Besides, some issues limit their wide use in the market, such as suitable methods for the culture and storage of these oxygen-sensitive microbes. The present review goes over the main points related to NGPs and gives a viewpoint on the key issues that still hinder their wide application. Furthermore, we have focused on the advancement in NGPs and human healthiness investigations by clarifying the limitations of traditional probiotic microorganisms, discussing the characteristics of emerging NGPs and defining their role in the management of certain ailments. Future research should emphasize the isolation, mechanisms of action of these probiotics, safety, and clinical efficacy in humans.
肠道微生物组研究的最新进展及持续突破表明,肠道微生物群作为潜在有益益生菌的未被探索来源具有重要作用。随着这些进展,公众对益生菌的认知度和接受度都在不断提高。因此,学术和产业研究致力于识别和研究新的微生物菌株,以开发下一代益生菌(NGP)。目前,人们对作为生物疗法的NGP兴趣日益浓厚,这类疗法可改变肠道微生物组并影响各种疾病的发展。在本研究中,我们聚焦于一些新兴且有前景的NGP,特别是哈氏真杆菌、普拉梭菌、罗氏菌属、嗜黏蛋白阿克曼氏菌和脆弱拟杆菌,因为它们在肠道中的存在会对各种疾病的发展产生影响。新兴研究指出了这些NGP的有益作用,并开辟了新的有前景的治疗选择。有趣的是,这些NGP被发现可增强胃肠道免疫力、提高癌症患者免疫治疗效果、维持肠道屏障完整性、产生有价值的代谢产物,尤其是短链脂肪酸,并减少化疗和放疗的并发症。尽管这些NGP中的许多被认为对预防和治疗多种慢性疾病具有潜力,但针对人类的研究仍然不足。因此,监管机构对这些微生物的批准很少。此外,一些问题限制了它们在市场上的广泛应用,例如这些对氧气敏感的微生物的合适培养和储存方法。本综述概述了与NGP相关的要点,并对仍然阻碍其广泛应用的关键问题发表了观点。此外,我们通过阐明传统益生菌微生物的局限性、讨论新兴NGP的特征并确定它们在某些疾病管理中的作用,聚焦于NGP和人类健康研究的进展。未来的研究应强调这些益生菌的分离、作用机制、安全性和在人类中的临床疗效。